Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

VERO vs INMD vs AEYE vs NVCR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
VERO
Venus Concept Inc.

Medical - Devices

HealthcareNASDAQ • CA
Market Cap$499K
5Y Perf.-99.9%
INMD
InMode Ltd.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$882M
5Y Perf.-6.7%
AEYE
AudioEye, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$100M
5Y Perf.-24.8%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-83.8%

VERO vs INMD vs AEYE vs NVCR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
VERO logoVERO
INMD logoINMD
AEYE logoAEYE
NVCR logoNVCR
IndustryMedical - DevicesMedical - DevicesSoftware - ApplicationMedical - Instruments & Supplies
Market Cap$499K$882M$100M$1.92B
Revenue (TTM)$59M$375M$40M$674M
Net Income (TTM)$-55M$87M$-3M$-173M
Gross Margin64.4%77.8%78.3%75.2%
Operating Margin-59.0%21.3%-7.9%-27.2%
Forward P/E9.6x
Total Debt$43M$13M$721K$290M
Cash & Equiv.$4M$303M$5M$103M

VERO vs INMD vs AEYE vs NVCRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

VERO
INMD
AEYE
NVCR
StockMay 20Apr 26Return
Venus Concept Inc. (VERO)1000.1-99.9%
InMode Ltd. (INMD)10093.3-6.7%
AudioEye, Inc. (AEYE)10075.2-24.8%
NovoCure Limited (NVCR)10016.2-83.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: VERO vs INMD vs AEYE vs NVCR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INMD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. AudioEye, Inc. is the stronger pick specifically for growth and revenue expansion. NVCR also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
VERO
Venus Concept Inc.
The Secondary Option

VERO lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
INMD
InMode Ltd.
The Income Pick

INMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 1.04
  • 105.0% 10Y total return vs AEYE's 102.2%
  • Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
  • Beta 1.04, current ratio 9.88x
Best for: income & stability and long-term compounding
AEYE
AudioEye, Inc.
The Growth Play

AEYE is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 14.5%, EPS growth 30.6%, 3Y rev CAGR 10.5%
  • 14.5% revenue growth vs VERO's -15.1%
Best for: growth exposure
NVCR
NovoCure Limited
The Momentum Pick

NVCR is the clearest fit if your priority is momentum.

  • +1.1% vs VERO's -88.5%
Best for: momentum
See the full category breakdown
CategoryWinnerWhy
GrowthAEYE logoAEYE14.5% revenue growth vs VERO's -15.1%
Quality / MarginsINMD logoINMD23.3% margin vs VERO's -92.8%
Stability / SafetyINMD logoINMDBeta 1.04 vs AEYE's 2.29, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)NVCR logoNVCR+1.1% vs VERO's -88.5%
Efficiency (ROA)INMD logoINMD11.8% ROA vs VERO's -88.6%, ROIC 13.5% vs -39.8%

VERO vs INMD vs AEYE vs NVCR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

VEROVenus Concept Inc.
FY 2024
System
58.6%$38M
Leases
20.5%$13M
Product
16.1%$10M
Service
4.7%$3M
INMDInMode Ltd.
FY 2025
Capital Equipment
100.0%$289M
AEYEAudioEye, Inc.
FY 2024
Enterprise
100.0%$15M
NVCRNovoCure Limited

Segment breakdown not available.

VERO vs INMD vs AEYE vs NVCR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINMDLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

INMD leads this category, winning 3 of 6 comparable metrics.

NVCR is the larger business by revenue, generating $674M annually — 16.7x AEYE's $40M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to VERO's -92.8%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricVERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AEYE logoAEYEAudioEye, Inc.NVCR logoNVCRNovoCure Limited
RevenueTrailing 12 months$59M$375M$40M$674M
EBITDAEarnings before interest/tax-$31M$81M-$504,000-$165M
Net IncomeAfter-tax profit-$55M$87M-$3M-$173M
Free Cash FlowCash after capex-$21M$91M$2M-$48M
Gross MarginGross profit ÷ Revenue+64.4%+77.8%+78.3%+75.2%
Operating MarginEBIT ÷ Revenue-59.0%+21.3%-7.9%-27.2%
Net MarginNet income ÷ Revenue-92.8%+23.3%-7.6%-25.7%
FCF MarginFCF ÷ Revenue-35.2%+24.2%+5.5%-7.1%
Rev. Growth (YoY)Latest quarter vs prior year-8.2%+5.3%+7.9%+12.3%
EPS Growth (YoY)Latest quarter vs prior year-8.5%-30.8%+29.0%-100.0%
INMD leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

VERO leads this category, winning 2 of 3 comparable metrics.
MetricVERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AEYE logoAEYEAudioEye, Inc.NVCR logoNVCRNovoCure Limited
Market CapShares × price$498,989$882M$100M$1.9B
Enterprise ValueMkt cap + debt − cash$39M$593M$96M$2.1B
Trailing P/EPrice ÷ TTM EPS-0.00x9.73x-32.36x-13.80x
Forward P/EPrice ÷ next-FY EPS est.9.64x
PEG RatioP/E ÷ EPS growth rate0.98x
EV / EBITDAEnterprise value multiple6.88x
Price / SalesMarket cap ÷ Revenue0.01x2.38x2.49x2.92x
Price / BookPrice ÷ Book value/share0.07x1.33x20.91x5.51x
Price / FCFMarket cap ÷ FCF10.46x
VERO leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

INMD leads this category, winning 6 of 9 comparable metrics.

INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-17 for VERO. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERO's 15.16x. On the Piotroski fundamental quality scale (0–9), VERO scores 5/9 vs INMD's 3/9, reflecting solid financial health.

MetricVERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AEYE logoAEYEAudioEye, Inc.NVCR logoNVCRNovoCure Limited
ROE (TTM)Return on equity-17.4%+13.3%-47.8%-50.8%
ROA (TTM)Return on assets-88.6%+11.8%-9.5%-16.5%
ROICReturn on invested capital-39.8%+13.5%-42.4%-16.4%
ROCEReturn on capital employed-54.2%+12.1%-17.7%-28.9%
Piotroski ScoreFundamental quality 0–95345
Debt / EquityFinancial leverage15.16x0.02x0.15x0.85x
Net DebtTotal debt minus cash$39M-$289M-$5M$187M
Cash & Equiv.Liquid assets$4M$303M$5M$103M
Total DebtShort + long-term debt$43M$13M$721,000$290M
Interest CoverageEBIT ÷ Interest expense-9.69x-2.79x-96.80x
INMD leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

AEYE leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in AEYE five years ago would be worth $3,977 today (with dividends reinvested), compared to $9 for VERO. Over the past 12 months, NVCR leads with a +1.1% total return vs VERO's -88.5%. The 3-year compound annual growth rate (CAGR) favors AEYE at 6.4% vs VERO's -79.4% — a key indicator of consistent wealth creation.

MetricVERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AEYE logoAEYEAudioEye, Inc.NVCR logoNVCRNovoCure Limited
YTD ReturnYear-to-date-82.3%-5.9%-18.7%+28.3%
1-Year ReturnPast 12 months-88.5%-2.1%-27.9%+1.1%
3-Year ReturnCumulative with dividends-99.1%-60.2%+20.6%-75.7%
5-Year ReturnCumulative with dividends-99.9%-63.9%-60.2%-91.3%
10-Year ReturnCumulative with dividends-100.0%+105.0%+102.2%+30.3%
CAGR (3Y)Annualised 3-year return-79.4%-26.4%+6.4%-37.6%
AEYE leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — INMD and NVCR each lead in 1 of 2 comparable metrics.

INMD is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs VERO's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricVERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AEYE logoAEYEAudioEye, Inc.NVCR logoNVCRNovoCure Limited
Beta (5Y)Sensitivity to S&P 5001.43x1.04x2.29x2.20x
52-Week HighHighest price in past year$12.93$16.74$16.39$20.06
52-Week LowLowest price in past year$0.26$12.72$5.31$9.82
% of 52W HighCurrent price vs 52-week peak+2.1%+83.2%+49.4%+83.9%
RSI (14)Momentum oscillator 0–10042.939.861.369.8
Avg Volume (50D)Average daily shares traded9K804K194K1.5M
Evenly matched — INMD and NVCR each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: INMD as "Buy", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 14.9% for INMD (target: $16).

MetricVERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AEYE logoAEYEAudioEye, Inc.NVCR logoNVCRNovoCure Limited
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$16.00$33.50
# AnalystsCovering analysts1115
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+14.5%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

INMD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VERO leads in 1 (Valuation Metrics). 1 tied.

Best OverallInMode Ltd. (INMD)Leads 2 of 6 categories
Loading custom metrics...

VERO vs INMD vs AEYE vs NVCR: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is VERO or INMD or AEYE or NVCR a better buy right now?

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -15. 1% for Venus Concept Inc. (VERO). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — VERO or INMD or AEYE or NVCR?

Over the past 5 years, AudioEye, Inc.

(AEYE) delivered a total return of -60. 2%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: INMD returned +105. 0% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — VERO or INMD or AEYE or NVCR?

By beta (market sensitivity over 5 years), InMode Ltd.

(INMD) is the lower-risk stock at 1. 04β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 120% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — VERO or INMD or AEYE or NVCR?

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -15. 1% for Venus Concept Inc. (VERO). On earnings-per-share growth, the picture is similar: AudioEye, Inc. grew EPS 30. 6% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — VERO or INMD or AEYE or NVCR?

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -41. 9% for VERO. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is VERO or INMD or AEYE or NVCR more undervalued right now?

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

07

Which pays a better dividend — VERO or INMD or AEYE or NVCR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is VERO or INMD or AEYE or NVCR better for a retirement portfolio?

For long-horizon retirement investors, InMode Ltd.

(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +105. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INMD: +105. 0%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between VERO and INMD and AEYE and NVCR?

These companies operate in different sectors (VERO (Healthcare) and INMD (Healthcare) and AEYE (Technology) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VERO is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; AEYE is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

VERO

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 38%
Run This Screen
Stocks Like

INMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 13%
Run This Screen
Stocks Like

AEYE

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 46%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform VERO and INMD and AEYE and NVCR on the metrics below

Revenue Growth>
%
(VERO: -8.2% · INMD: 5.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.